Dermata Therapeutics, Inc. (DRMA) Form 8-K — Aug 17, 2026
Dermata Therapeutics entered into securities purchase agreements on August 16, 2026 for a private placement of 933,064 common shares plus pre-funded warrants covering up to 1,360,544 shares, priced at $1.46 and $1.459 respectively, with estimated net proceeds of approximately $3.2 million. Every purchase also carries Series E and Series F warrants covering up to 2,293,608 shares each at a $1.46 exercise price; the Series E warrants run five years and the Series F warrants twenty-four months from stockholder approval, and the placement bank received a 35,958-share tail warrant at $1.825 plus a $52,500 cash fee.
Key figures
- Offering Price
- 1.46
- Shares Offered
- 933,064 shares plus pre-funded warrants for 1,360,544 shares
- Net Proceeds Custom
- approximately $3.2 million after offering expenses
- Bank Cash Fee
- 52500
- Series ETerm
- 5 years from stockholder approval
- Series FTerm
- 24 months from stockholder approval
- Bank Warrant Shares
- 35958
- Insider Share Price
- 1.47
- Series EWarrant Shares
- 2293608
- Series FWarrant Shares
- 2293608
- Warrant Exercise Price
- 1.46
- Insider Pre Funded Price
- 1.469
- Pre Funded Warrant Shares
- 1360544
- Bank Warrant Exercise Price
- 1.825
- Beneficial Ownership Limit
- 4.99% (electable to 9.99%)
- Insider Aggregate Purchase
- approximately $2.4 million
- Pre Funded Warrant Unit Price
- 1.459
- Insider Securities Purchased
- 4897956
- Registration Filing Deadline
- 60 days from registration rights agreement
- Pre Funded Warrant Exercise Price
- 0.001
- Registration Effectiveness Deadline
- 90 days (120 if full SEC review)
Price after filing
Close on the filing date to close N calendar days later (from $1.46). Historical, not a forecast.
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.